Dogwood's Halneuron® Milestone Offers Hope for Chronic Chemo-Induced Pain

ATLANTA, GA – July 20, 2026 – Dogwood Therapeutics (Nasdaq: DWTX) today announced a significant step forward in the quest for a non-opioid solution to a debilitating side effect of cancer treatment, confirming the enrollment of its first 200 patients in a pivotal Phase 2b trial for its lead candidate, Halneuron®. The drug targets chemotherapy-induced neuropathic pain (CINP), a chronic condition that affects millions of cancer survivors and for which effective, safe treatments are desperately lacking.

The announcement brings a fresh wave of optimism, not just for the Atlanta-based biotech firm, but for the vast patient population grappling with the painful legacy of their life-saving cancer therapies. Bolstering this optimism is a prior finding from an independent statistical review committee, which concluded that patients treated with Halneuron® were already showing "separation from placebo" in pain improvement—a crucial early indicator of the drug's potential efficacy. With top-line data from the study now anticipated in the fall of 2026, all eyes are on Dogwood as it navigates the final stages of this critical trial.

The Unseen Cost of Cancer Survival

For a significant portion of cancer survivors, the battle doesn't end with remission. Up to 60% of patients who undergo treatment with common chemotherapies, particularly platinum-based drugs and taxanes, develop chemotherapy-induced neuropathic pain. This chronic condition manifests as burning sensations, tingling, numbness, and sharp pain, typically in the hands and feet, often described in a "stocking-glove" pattern. The impact on quality of life is profound, affecting everything from sleep and mobility to the ability to perform simple daily tasks. In some cases, the pain is so severe that it forces oncologists to reduce chemotherapy dosage or halt treatment altogether, compromising the chances of a successful cancer outcome.

The current treatment landscape for CINP is starkly inadequate. Medical experts note that despite its prevalence, there is a severe lack of approved, effective therapies. Duloxetine, an antidepressant, is the only drug that has demonstrated some consistent benefit, but it is not universally effective and comes with its own side effect profile. Physicians often turn to off-label prescriptions, including anti-seizure medications and other antidepressants, which offer limited relief and can carry a heavy burden of central nervous system side effects. Opioids, while powerful, are generally considered a last resort for chronic neuropathic pain due to their ineffectiveness for this type of pain, significant side effects, and high potential for addiction—a risk few patients or doctors are willing to take. This glaring therapeutic gap represents one of the most significant unmet needs in oncology supportive care.

A Targeted Attack on Pain Signals

Halneuron® represents a fundamentally different approach to managing CINP. Developed by Dogwood Therapeutics, it is a first-in-class, non-opioid analgesic that works by selectively modulating the NaV 1.7 sodium channel. These channels are critical gateways for pain signals, located predominantly in peripheral nerve cells. By specifically targeting NaV 1.7, Halneuron® aims to block the transmission of pain signals at their source, before they can reach the brain. This precision targeting holds the promise of effective pain relief without the systemic, off-target effects associated with opioids or broader-acting drugs.

The potential of this approach has already been recognized by regulators. The U.S. Food and Drug Administration (FDA) has granted Halneuron® Fast Track designation, a status reserved for drugs that treat serious conditions and fill an unmet medical need. This designation is intended to expedite the development and review process, underscoring the urgency of getting new treatments like Halneuron® to patients.

The ongoing Phase 2b trial, known as HAL-CINP, is a randomized, placebo-controlled study designed to rigorously assess the drug's efficacy and safety. Approximately 210 to 240 patients across 25 U.S. sites will receive either Halneuron® or a placebo via subcutaneous injection over a two-week period, with follow-up for a total of 28 days. A key metric shared by the company is the trial's exceptionally low dropout rate of just 4.5%. "The continued low dropout rate... remains below rates typically observed in studies of other FDA-approved chronic pain medicines and is consistent with the encouraging safety and tolerability profile observed in prior Halneuron® clinical trials," said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. This suggests patients are tolerating the treatment well, a critical factor for any chronic pain therapy's real-world success.

Decoding the Signals for Investors

For a development-stage company like Dogwood, clinical milestones are the currency of progress, and this latest announcement is a significant deposit. Successfully enrolling 200 patients moves the HAL-CINP trial closer to its final readout and serves as a powerful execution signal to the market. However, the most strategically important detail for investors may be the one buried in the second paragraph of the company's press release: the December finding from an independent statistical review committee.

The committee's conclusion that Halneuron® demonstrated "separation from placebo" is a potent piece of business intelligence. In the high-stakes world of drug development, such an interim finding from an unblinded review significantly de-risks the clinical asset. It provides the first statistically relevant glimpse that the drug is performing as intended, giving the company and its investors a strong reason to believe the trial is on track to meet its primary endpoint—a change in patients' weekly average pain scores.

This positive signal, combined with the low dropout rate and Fast Track status, paints a compelling picture for Dogwood's lead candidate. The potential market is substantial; the global neuropathic pain market was valued at over $42 billion in 2024 and is projected to exceed $60 billion by 2031, driven by an aging population and a growing number of cancer survivors. A safe, effective, non-opioid treatment specifically for CINP would likely capture a significant share of this market, transforming Dogwood from a development-stage company into a commercial player. The upcoming top-line data in Fall 2026 is now a major catalyst on the horizon for investors.

A Pipeline for Nerve Repair and Recovery

While Halneuron® is rightfully in the spotlight, Dogwood's strategic vision extends beyond pain signal modulation. The company's research pipeline includes a second promising candidate, SP16 IV, which takes a different, potentially complementary, approach to neuropathy. SP16 IV is an agonist for the LRP1 receptor, a protein involved in nerve repair and reducing inflammation.

Where Halneuron® acts as a roadblock for pain signals, SP16 IV has the preclinical potential to act as a repair crew, addressing the underlying nerve damage caused by chemotherapy. Its mechanism has been shown in preclinical studies to reduce key inflammatory markers and promote pathways involved in cell growth and survival. This dual-pronged strategy—managing symptoms with Halneuron® while potentially repairing damage with SP16 IV—positions Dogwood at the forefront of a more holistic approach to treating neuropathic disorders.

Significantly, the forthcoming Phase 1b trial for SP16 IV is fully funded by the National Cancer Institute (NCI). This non-dilutive funding is not only a financial boon for the company, but it also serves as a powerful external validation of its scientific platform from one of the world's leading biomedical research agencies. It demonstrates that Dogwood's approach to nerve repair is considered scientifically sound and worthy of federal investment, adding another layer of credibility to the company's overall strategy and long-term potential.